Trial Condition(s):
Bone Neoplasms
Bonefos and the consumption of analgesics (BICAM)
Bayer Identifier:
14236
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
Inclusion Criteria
- Breast cancer or prostate cancer or multiple myeloma. - Bone metastasis. - Ability to use analgesics and clodronate 1600 mg/day.
Exclusion Criteria
- Hypersensitivity to bisphosphonates. - Clodronate in previous therapy. - Concomitant use of other bisphosphonates. - Serious renal insufficiency.
Trial Summary
Enrollment Goal
149
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Bonefos (Clodronate, BAY94-8393)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
| Locations | |
|---|---|
Locations Investigative Site Many locations, Czech Republic | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Bonefos and the consumption of analgesics. Influence of clodronate on analgesics consumption among patients with bone metastasis
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myelomaTimeframe: 12 months
Secondary Outcome
- Decrease in pain measured by VAS (Visual Analogue Scale)Timeframe: 12 months
Additional Information
Copyright © Bayer
Powered by
